vTv Therapeutics VTVT 深 沪
等待开盘 10-14 09:30:00 美东时间
28.23
-2.230
-7.32%
华盛通- 最 高31.215
- 今 开30.75
- 成交量 4.20万股
- 最 低 27.87
- 昨 收 30.46
- 总市值 1.12亿
- 52周最高 44.00
- 市盈率 静 --
- 换手率 1.06%
- 52周最低 19.80
- 委 比 20.48%
- 总股本 395.40万
- 历史最高 560.00
- 量 比 1.64
- 振 幅 10.98%
- 历史最低 7.38
- 每 手 1
- 风险率 4.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多国产PDE4B抑制剂III期头对头赢下安进
（来源：求实药社） 10月9日，cAMPfield Therapeutics与恒翼生物（Newsoara Biopharma）公布口服PDE4B选择性抑制剂普瑞...
10-12 11:51
vTv Therapeutics Completes Enrollment In Its Phase 3 Cadisegliatin As Adjunctive Therapy In Type 1 Diabetes Trial
vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that the Company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes (CATT1...
10-05 20:09
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 2,500 stock options to a non-executive employee under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.44 per share, vest over four years, and expire in 10 years. The company is focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, currently in a US Phase 3 trial. Cadisegliatin has received Breakthrough Therapy designation from the FDA.
09-15 20:05
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics授予非执行员工2,500股股票期权，作为就业激励，行权价为每股31.48美元，分4年归属，10年有效期。该期权依据纳斯达克上市规则授予。vTv专注于开发治疗糖尿病的口服药物cadisegliatin，目前处于美国III期临床试验阶段，为潜在同类首创新药。cadisegliatin是一种肝选择性葡萄糖激酶激活剂，已获FDA突破性疗法认定。投资者和媒体联系方式已提供。
08-19 20:05
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and lowers the price target from $45 to $42.
08-07 02:43
vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 14.13 percent decrease over losses of $(0.92) per share from the same period last year.
08-06 20:12
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics granted 23,500 stock options to two non-executive employees, with a weighted average exercise price of $31.95 per share. The options vest over four years and have a 10-year term. The company is focused on developing cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes, currently in a US Phase 3 trial.
07-28 20:05
美股大行评级 | 阿斯麦、贝莱德、纽约梅隆银行、信达思、JB亨特运输服务、美国制商银行、PNC金融服务集团等获多家大行集体上调目标价
今日重点评级关注：瑞杰金融：维持Electrovaya"强力买入"评级，目标价从14美元升至22美元；BTIG：维持vTv Therapeutics"买入"评级，目标价从49美元升至57美元
07-17 11:35
BlackRock To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised the price target for J B Hunt Transport Services Inc (NASDAQ:JBHT) from $290 to $320. Baird analy...
07-16 19:57
